Histopathological Evaluation and Analysis of Immunohistochemical Expression of Bcl-2 Oncoprotein in Colorectal Carcinoma
- PMID: 31754362
- PMCID: PMC6824766
- DOI: 10.30699/ijp.2019.102982.2028
Histopathological Evaluation and Analysis of Immunohistochemical Expression of Bcl-2 Oncoprotein in Colorectal Carcinoma
Abstract
Background & objective: Colorectal cancer is the third most prevalent malignancy with high mortality rate, necessitating markers that predict survival and guide the treatment. Previous studies have examined the immunohistochemical expression of Bcl-2, an apoptotic marker, in colorectal carcinoma, but results have been contradictory. To evaluate the histopathological features of colorectal carcinoma, immunohistochemical expression of Bcl-2 must be analyzed to find out statistical association of Bcl-2 expression with certain prognostic factors histopathologic type, grade and TNM staging.
Methods: This prospective study was conducted on the colectomy specimens of colorectal carcinoma, over a period of two years. The tumor morphology and Bcl-2 status were evaluated by immunohistochemistry in each case.
Results: The study included 58 cases, with mean patient age of 47.07 years and male: female ratio of 1.89:1. Bcl-2 positivity was seen in 32.7% of the cases. Weak, moderate, and strong expression of Bcl-2 was seen in 12.1%, 12.1%, and 8.5% of cases respectively. Even though early stages of colorectal carcinoma showed greater frequency of Bcl-2 expression than advanced stages (36.3% versus 28%), however this association was not statistically significant.
Conclusion: Lack of statistically significant correlation between Bcl-2 immuno-histochemical expression and prognostic parameters like tumor grade and stage, suggests that Bcl-2 immunoexpression may not be a significant prognostic marker in colorectal carcinoma.
Keywords: Colorectal carcinomas; Immunohistochemistry; Prognostic factors.
Conflict of interest statement
The authors declared that there is no conflict of interest regarding the publication of this article.
References
-
- Vasile L, Olaru A, Munteanu M, Plesea IE, Surlin V, Tudorascu C. Prognosis of colorectal cancer: clinical, pathological and therapeutic correlation. Rom J Morphol Embryol. 2012;53(2):383–91. - PubMed
-
- Hegazy A, Daoud SA, Ibrahim WS, El-Atrebi K, Saker M, Abdel-Wahab N. Role of Ki- 67, p53 and Bcl-2 in Advanced colorectal carcinoma (Histopathological and Immunohistochemical study) Academic J Cancer Res. 2014;7:168–72.
-
- Papagiorgis PC, Zizi AE, Tseleni S, Oikonomakis IN, Sofras L, Patsouris E. Disparate clinicopathological correlations of p53 and Bcl-2 in colorectal cancer. Mol Med Rep. 2012;5:377–82. - PubMed
-
- Luderer LA, Lustosa SAS, Silva SEM, Denadai MVA, AfonsoJr RJ, Viana LS. Significance of a Biomarkers Immunohistochemistry Panel for Survival Prognostic in Patients with Sporadic colorectal cancer. Ann Clin Pathol . 2015;3:1050–61.
-
- Menezes HL, Juca MJ, Gomes EG, Nunes BL, Costa HO, Matos D. Analysis of the immunohistochemical expressions of p53, Bcl-2 and Ki-67 in colorectal adenocarcinoma and their correlation with the prognostic factors. Arq Gastroenterol . 2010;47:141–7 . - PubMed
LinkOut - more resources
Full Text Sources